-

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Fidelis Insurance Holdings Limited (FIHL)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Fidelis Insurance Holdings Limited (“Fidelis” or the “Company”) (NYSE: FIHL). The investigation concerns whether Fidelis and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

On June 29, 2023, Fidelis commenced its initial public offering, selling 15 million shares of common stock priced at $14.00 per share. On November 20, 2023, Fidelis announced its financial results for the third quarter of 2023. Among other items, Fidelis disclosed GAAP earnings per share of $0.74, missing consensus estimates by $0.13, and total revenues of $537.5 million, missing consensus estimates by $49.81 million. On this news, the price of Fidelis shares declined by $1.38 per share, or approximately 9.59%, from $14.39 per share to close at $13.01 on November 21, 2023.

If you purchased or otherwise acquired Fidelis securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: https://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:FIHL

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

SPORTRADAR GROUP AG INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Sportradar Group AG (“Sportradar” or the “Company”) (NASDAQ:SRAD). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 22, 2026, Muddy Waters Research published a report alleging, among other things, that Sp...

NANO-X IMAGING LTD. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ:NNOX). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 20, 2026, Nano-X announced its fourth quarter 2025 financial results. Among other items, Nan...

ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until May 29, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this de...
Back to Newsroom